Table 2.
Baseline characteristics of participants, by reporting mode
| Internet | Telephone | Total | |
|---|---|---|---|
| Completed, n (% of total) | 290 (84.3%) | 54 (15.7%) | 344 (100%) |
| Completed by: n (%) | |||
| Patient | 277 (95.5%) | 54 (100%) | 331 (96.2%) |
| Carer | 6 (2.1%) | 0 (0%) | 6 (1.7%) |
| Parent | 7 (2.4%) | 0 (0%) | 7 (2.0%) |
| Age, mean years (range) | 51.4 (13-77)a | 61.5 (35-82) | 53.1 (13-82) |
| Sex, n (%) M/F | 103/166 (38.3/61.7) | 19/35 (35.2/64.8) | 122/201 (37.8/62.2) |
| Diagnosis, n (%) [mean age, %F] | |||
| Rheumatoid arthritis | 152 (79.6%) [53.9, 72%] | 39 (20.4)% [64.4, 67%] | 191 (100%)[56.0, 71%] |
| Psoriasis | 31 (88.6%) [48.2, 52%] | 4 (11.4%) [61.2, 75%] | 35 (100%) [49.8, 62%] |
| Ankylosing spondylitis | 40 (93.0%)[49.1, 25%] | 3 (7.0%) [51.3, 33%] | 43 (100%) [49.2, 26%] |
| Psoriatic arthritis | 37 (84.1%) 50.3, 68%] | 7 (15.9%) [51.9, 71%] | 44 (100%) [50.5, 68%] |
| Otherb | 30 (96.8%) [41.7, 63%] | 1 (3.2%) [48.0, 0%] | 31 (100%) [42.1, 62%] |
| Previous biologics | |||
| N | 275 | 54 | 329 |
| Any | 59 (21.5%) | 6 (11.1%) | 65 (19.8%) |
| Adulimumab | 43 (15.6%) | 5 (9.3%) | 48 (14.6%) |
| Infliximab | 11 (4.0%) | 1 (1.9%) | 12 (3.6%) |
| Current medications | |||
| N | 277 | 54 | 331 |
| Methotrexate | 120 (43.3%) | 29 (53.7%) | 149 (45.0%) |
| Sulfasalazine | 46 (16.6%) | 7 (13.0%) | 53 (16.0%) |
| Prednisolone | 55 (19.9%) | 14 (25.9%) | 69 (20.8%) |
| Quality of life | |||
| CGI-S | |||
| N | 275 | 54 | 329 |
| N ( %) ≥markedly ill) | 184 (66.9%) | 30 (55.6%) | 214 (65.0%) |
| EQ-5D | |||
| N | 265 | 54 | (0.35) |
| EQ5D Index, Mean (SD) | 0.41 (0.36) | 0.45 (0.29) | 0.42 |
| N | 139 | 20 | 159 |
| EQ5D VAS, Mean (SD) | 47.6 (23.0) | 51.2 (21.8) | 48.1 (22.8) |
| HAQ | |||
| N | 151 | 190 | |
| Mean (SD) | 1.68 (0.64)c | 1.97 | 1.74 (0.65) |
| DLQI | |||
| N | 31 | 4 | 35 |
| Mean (SD) | 15.5 (8.1) | 11.8 (3.4) | 15.0 (7.8) |
a Statistically significant difference between Internet and telephone users, p < 0.001 (Wilcoxon test)
b Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?'
c Statistically significant difference between Internet and telephone users, p = 0.003 (Wilcoxon test), p = 0.010 (t-test)